According to a review of global pharmaceutical markets [1], tigecycline is an antibiotic used to treat certain bacterial infections, but access to this medication has been limited due to a lack of generic competitors. The initial patent for tigecycline expired in 2016 in the United States.

However, since then, no reliable generic versions of tigecycline have entered the market [2]. In 2020, the U.S. Food and Drug Administration (FDA) approved the first generic version of tigecycline, manufactured by Teva Pharmaceuticals, but the medication's manufacturer, Pfizer, challenged the approval of the generic version and the court's decision, which may impact its availability.

The lack of reliable supply chain for tigecycline generics raises concerns about the medication's pricing and availability, particularly for patients who rely on this antibiotic for their treatment [3]. According to DrugPatentWatch.com [4], there are several other companies developing tigecycline generics, but none of these products have yet been approved by regulatory authorities.

It remains to be seen whether additional generic versions of tigecycline will emerge in the coming years, which could potentially address these concerns and facilitate greater access to this essential medication.

Sources:

[1] "Global Pharmaceutical Market Review" - Statista.com (accessed 2023)

[2] "Tigecycline - Medicines: Tetracycline antibiotics" by MedlinePlus, (accessed 2023)

[3] "Teva wins FDA approval for generic Zavzpret" - by Pharmaceutical Journal, 24th of November, 2022.

[4] https://www.drugpatentwatch.com/drugs/0000300019/tigecycline